INTRODUCTION

Rituximab (brand names MabThera, Riabni, Rituxan, Rituxan Hycela, Ruxience, Truxima) is a chimeric murine/human monoclonal antibody that binds to CD20 antigen. Rituximab is used to treat certain autoimmune diseases and types of cancers including non-Hodgkin's lymphoma, chronic lymphocytic leukemia, Wegener's granulomatosis, pemphigus vulgaris, and rheumatoid arthritis.

This plasmid is designed for expressing Rituximab in mammalian expression system such as HEK293 or Chinese hamster ovary (CHO) cell line.

PRODUCT INFORMATION

Item No.: PPBD-161
Shipping: Lyophilized plasmid, or liquid plasmid, or plasmids on filter paper
Storage: -20 °C or 4°C according to instruction
Plasmid Backbone: Expression plasmid, flexible options, custom available
Quality Control: Sequencing validation

DRUG INFORMATION

Generic Name: Rituximab
Brand Name(s): MabThera, Riabni, Rituxan, Rituxan Hycela, Ruxience, Truxima
Classification: Monoclonal antibody (mAb)
Target: CD20
Amino Acid Sequence: Identical to DB00073

PROTOCOL FOR PLASMID RECOVERY FROM FILTER PAPER

REFERENCE

[1] McLaughlin P, Grillo-López AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Bruckler I, White CA, Cabanillas F, Jain V, Ho AD, Lister J, Wey K, Shen D, Dallaire BK. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998 Aug;16(8):2825-33.

[2] Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, Stevens RM, Shaw T. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med. 2004 Jun 17;350(25):2572-81.

Contact Us